Dosing and uses of Azopt (brinzolamide)
Adult dosage forms and strengths
ophthalmic suspension
- 1%
Ocular Hypertension or Open-Angle Glaucoma
1 gtt in affected eye q8hr
Administration
May be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure; if more than one topical ophthalmic drug being used, administer at least ten min apart
Pediatric dosage forms and strengths
Safety & efficacy not established
Azopt (brinzolamide) adverse (side) effects
1-10%
Blurred vision (1-5%)
Bitter, sour or unusual taste (1-5%)
Blepharitis (1-5%)
Dermatitis (1-5%)
Dry eye (1-5%)
Foreign body sensation (1-5%)
Headache (1-5%)
Hyperemia (1-5%)
Ocular discharge (1-5%)
Ocular discomfort (1-5%)
Ocular keratitis (1-5%)
Ocular pain (1-5%)
Ocular pruritus (1-5%)
Rhinitis (1-5%)
<1%
Allergic reactions
Alopecia
Chest pain
Conjunctivitis
Diarrhea
Diplopia
Dizziness
Dry mouth
Dyspnea
Dyspepsia
Eye fatigue
Hypertonia
Keratoconjunctivitis
Keratopathy
Kidney pain
Lid margin crusting or sticky sensation
Nausea
Pharyngitis
Tearing
Urticaria
Stevens-Johnson syndrome
Toxic epidermal necrolysis
Fulminant hepatic necrosis
Agranulocytosis
Aplastic anemia
Other blood dyscrasias
Warnings
Contraindications
Hypersensitivity
Severe renal impairment (CrCl <30 mL/min)
Cautions
Hepatic impairment
Corneal edema may occur in patients with low endothelial cell counts
Pregnancy and lactation
Pregnancy category: C
Lactation: Not known if distributed in breast milk; not recommedned (discontinue drug or do not nurse)
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Azopt (brinzolamide)
Mechanism of action
Inhibits carbonic anhydrase inhibitor, which in turn causes aqueous humor secretion to decreases
Pharmacokinetics
Half-Life: 3.5-4 mo
Absorption: Some systemic
Distribution: to RBCs
Protein binding: 60%
Excretion: Urine
